{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:20:11Z","timestamp":1778901611423,"version":"3.51.4"},"reference-count":49,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["#2\/2018"],"award-info":[{"award-number":["#2\/2018"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["Task Force for Cystic Fibrosis"],"award-info":[{"award-number":["Task Force for Cystic Fibrosis"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Cinque per Mille e Ricerca Corrente Linea 1"],"award-info":[{"award-number":["Cinque per Mille e Ricerca Corrente Linea 1"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein is expressed at the apical plasma membrane (PM) of different epithelial cells. The most common mutation responsible for the onset of cystic fibrosis (CF), F508del, inhibits the biosynthesis and transport of the protein at PM, and also presents gating and stability defects of the membrane anion channel upon its rescue by the use of correctors and potentiators. This prompted a multiple drug strategy for F508delCFTR aimed simultaneously at its rescue, functional potentiation and PM stabilization. Since ganglioside GM1 is involved in the functional stabilization of transmembrane proteins, we investigated its role as an adjuvant to increase the effectiveness of CFTR modulators. According to our results, we found that GM1 resides in the same PM microenvironment as CFTR. In CF cells, the expression of the mutated channel is accompanied by a decrease in the PM GM1 content. Interestingly, by the exogenous administration of GM1, it becomes a component of the PM, reducing the destabilizing effect of the potentiator VX-770 on rescued CFTR protein expression\/function and improving its stabilization. This evidence could represent a starting point for developing innovative therapeutic strategies based on the co-administration of GM1, correctors and potentiators, with the aim of improving F508del CFTR function.<\/jats:p>","DOI":"10.3390\/ijms21124486","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T08:54:50Z","timestamp":1592988890000},"page":"4486","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease"],"prefix":"10.3390","volume":"21","author":[{"given":"Giulia","family":"Mancini","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Loberto","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-0364","authenticated-orcid":false,"given":"Debora","family":"Olioso","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement, University of Verona, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7357-2104","authenticated-orcid":false,"given":"Maria Cristina","family":"Dechecchi","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement, University of Verona, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Cabrini","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement, University of Verona, 37134 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosaria","family":"Bassi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domitilla","family":"Schiumarini","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-9207","authenticated-orcid":false,"given":"Elena","family":"Chiricozzi","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9523-9054","authenticated-orcid":false,"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[{"name":"Section of Clinical Biochemistry, Department of Neurosciences, Biomedicine and Movement, University of Verona, 37134 Verona, Italy"},{"name":"Section of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, 37126 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Pesce","sequence":"additional","affiliation":[{"name":"U.O.C. Genetica Medica, IRCCS Giannina Gaslini, 16147 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Sonnino","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5161-1720","authenticated-orcid":false,"given":"Nicoletta","family":"Pedemonte","sequence":"additional","affiliation":[{"name":"U.O.C. Genetica Medica, IRCCS Giannina Gaslini, 16147 Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Tamanini","sequence":"additional","affiliation":[{"name":"Section of Molecular Pathology, Department of Pathology and Diagnostics, University Hospital of Verona, 37126 Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Aureli","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milano, LITA, Via Fratelli Cervi 93, 20090 Segrate, Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1183\/09031936.03.00057003","article-title":"New concepts of the pathogenesis of cystic fibrosis lung disease","volume":"23","author":"Boucher","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Accurso, F.J. (1997). Early pulmonary disease in cystic fibrosis. Curr. Opin. Pulm. Med.","DOI":"10.1097\/00063198-199711000-00002"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Van Goor, F., Hadida, S., Grootenhuis, P.D.J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., and Hazlewood, A. (2009). Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA.","DOI":"10.1016\/S1569-1993(09)60072-2"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Van Goor, F., Hadida, S., Grootenhuis, P.D.J., Burton, B., Stack, J.H., Straley, K.S., Decker, C.J., Miller, M., McCartney, J., and Olson, E.R. (2011). Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA.","DOI":"10.1073\/pnas.1105787108"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Favia, M., Mancini, M.T., Bezzerri, V., Guerra, L., Laselva, O., Abbattiscianni, A.C., Debellis, L., Reshkin, S.J., Gambari, R., and Cabrini, G. (2014). Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells. Am. J. Physiol. Lung Cell. Mol. Physiol.","DOI":"10.1152\/ajplung.00305.2013"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M.A., McKone, E.F., Ramsey, B.W., Rowe, S.M., Sass, L.A., and Tullis, E. (2018). VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1807120"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1753466619844424","DOI":"10.1177\/1753466619844424","article-title":"The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: Clinical evidence and future prospects in cystic fibrosis therapy","volume":"13","author":"Lommatzsch","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Taylor-Cousar, J.L., Mall, M.A., Ramsey, B.W., McKone, E.F., Tullis, E., Marigowda, G., McKee, C.M., Waltz, D., Moskowitz, S.M., and Savage, J. (2019). Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res.","DOI":"10.1183\/23120541.00082-2019"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Yu, H., Burton, B., Huang, C.J., Worley, J., Cao, D., Johnson, J.P., Urrutia, A., Joubran, J., Seepersaud, S., and Sussky, K. (2012). Ivacaftor potentiation of multiple CFTR channels with gating mutations. J. Cyst. Fibros.","DOI":"10.1016\/j.jcf.2011.12.005"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Van Goor, F., Yu, H., Burton, B., and Hoffman, B.J. (2014). Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. J. Cyst. Fibros.","DOI":"10.1016\/j.jcf.2013.06.008"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cheng, S.H., Gregory, R.J., Marshall, J., Paul, S., Souza, D.W., White, G.A., O\u2019Riordan, C.R., and Smith, A.E. (1990). Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell.","DOI":"10.1016\/0092-8674(90)90148-8"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21592","DOI":"10.1016\/S0021-9258(20)80582-1","article-title":"The \u0394F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells","volume":"268","author":"Lukacs","year":"1993","journal-title":"J. Biol. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., Crystal, R.G., Pavirani, A., Lecocq, J.P., and Lazdunski, M. (1991). Altered chloride ion channel kinetics associated with the \u0394F508 cystic fibrosis mutation. Nature.","DOI":"10.1038\/354526a0"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pedemonte, N., Lukacs, G.L., Du, K., Caci, E., Zegarra-Moran, O., Galietta, L.J.V., and Verkman, A.S. (2005). Small-molecule correctors of defective \u0394F508-CFTR cellular processing identified by high-throughput screening. J. Clin. Investig.","DOI":"10.1172\/JCI24898"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pesci, E., Bettinetti, L., Fanti, P., Galietta, L.J.V., La Rosa, S., Magnoni, L., Pedemonte, N., Sardone, G.L., and Maccari, L. (2015). Novel Hits in the Correction of \u03b4f508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis. J. Med. Chem.","DOI":"10.1021\/acs.jmedchem.5b00771"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Van Goor, F., Straley, K.S., Cao, D., Gonz\u00e1lez, J., Hadida, S., Hazlewood, A., Joubran, J., Knapp, T., Makings, L.R., and Miller, M. (2006). Rescue of \u0394F508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am. J. Physiol. Lung Cell. Mol. Physiol.","DOI":"10.1152\/ajplung.00169.2005"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wainwright, C.E., Elborn, J.S., Ramsey, B.W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J.C., De Boeck, K., and Flume, P.A. (2015). Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for phe508del CFTR. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1409547"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Taylor-Cousar, J.L., Munck, A., McKone, E.F., Van Der Ent, C.K., Moeller, A., Simard, C., Wang, L.T., Ingenito, E.P., McKee, C., and Lu, Y. (2017). Tezacaftor\u2013ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1709846"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Cholon, D.M., Quinney, N.L., Fulcher, M.L., Esther, C.R., Das, J., Dokholyan, N.V., Randell, S.H., Boucher, R.C., and Gentzsch, M. (2014). Cystic fibrosis: Potentiator ivacaftor abrogates pharmacological correction of \u0394F508 CFTR in cystic fibrosis. Sci. Transl. Med.","DOI":"10.1126\/scitranslmed.3008680"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Veit, G., Avramescu, R.G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P.M., Borot, F., Szollosi, D., Wu, Y.-S., and Finkbeiner, W.E. (2014). Some gating potentiators, including VX-770, diminish \u0394F508-CFTR functional expression HHS Public Access. Sci. Transl. Med. July.","DOI":"10.1126\/scitranslmed.3008889"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Matthes, E., Goepp, J., Carlile, G.W., Luo, Y., Dejgaard, K., Billet, A., Robert, R., Thomas, D.Y., and Hanrahan, J.W. (2016). Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor). Br. J. Pharmacol.","DOI":"10.1111\/bph.13365"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Davies, J.C., Moskowitz, S.M., Brown, C., Horsley, A., Mall, M.A., McKone, E.F., Plant, B.J., Prais, D., Ramsey, B.W., and Taylor-Cousar, J.L. (2018). VX-659-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa1807119"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Heijerman, H.G.M., McKone, E.F., Downey, D.G., Van Braeckel, E., Rowe, S.M., Tullis, E., Mall, M.A., Welter, J.J., Ramsey, B.W., and McKee, C.M. (2019). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial. Lancet.","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Swiatecka-Urban, A., Duhaime, M., Coutermarsh, B., Karlson, K.H., Collawn, J., Milewski, M., Cutting, G.R., Guggino, W.B., Langford, G., and Stanton, B.A. (2002). PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem.","DOI":"10.1074\/jbc.M206964200"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Guerra, L., Fanelli, T., Favia, M., Riccardi, S.M., Busco, G., Cardone, R.A., Carrabino, S., Weinman, E.J., Reshkin, S.J., and Conese, M. (2005). Na+\/H+ exchanger regulatory factor isoform 1 overexpression modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway 16HBE14o-cells and rescues \u0394F508 CFTR functional expression in cystic fibrosis cells. J. Biol. Chem.","DOI":"10.1074\/jbc.M505103200"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Favia, M., Guerra, L., Fanelli, T., Cardone, R.A., Monterisi, S., Di Sole, F., Castellani, S., Chen, M., Seidler, U., and Reshkin, S.J. (2010). Na+\/H+ exchanger regulatory factor 1 overexpression-dependent increase of cytoskeleton organization is fundamental in the rescue of F508del cystic fibrosis transmembrane conductance regulator in human airway CFBE41o-cells. Mol. Biol. Cell.","DOI":"10.1091\/mbc.e09-03-0185"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Haggie, P.M., Kim, J.K., Lukacs, G.L., and Verkman, A.S. (2006). Tracking of quantum dot-labeled CFTR shows near immobilization by C-terminal PDZ interactions. Mol. Biol. Cell.","DOI":"10.1091\/mbc.e06-08-0670"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Jin, S., Haggie, P.M., and Verkman, A.S. (2007). Single-particle tracking of membrane protein diffusion in a potential: Simulation, detection, and application to confined diffusion of CFTR Cl-channels. Biophys. J.","DOI":"10.1529\/biophysj.106.102244"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Moyer, B.D., Duhaime, M., Shaw, C., Denton, J., Reynolds, D., Karlson, K.H., Pfeiffer, J., Wang, S., Mickle, J.E., and Milewski, M. (2000). The PDZ-interacting domain of cystic fibrosis transmembrane conductance regulator is required for functional expression in the apical plasma membrane. J. Biol. Chem.","DOI":"10.1016\/S0021-9258(19)61481-X"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Short, D.B., Trotter, K.W., Reczek, D., Kreda, S.M., Bretscher, A., Boucher, R.C., Stutts, M.J., and Milgram, S.L. (1998). An apical PDZ protein anchors the cystic fibrosis transmembrane conductance regulator to the cytoskeleton. J. Biol. Chem.","DOI":"10.1074\/jbc.273.31.19797"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sun, F., Hug, M.J., Bradbury, N.A., and Frizzell, R.A. (2000). Protein kinase A associates with cystic fibrosis transmembrane conductance regulator via an interaction with ezrin. J. Biol. Chem.","DOI":"10.1074\/jbc.275.19.14360"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Monterisi, S., Favia, M., Guerra, L., Cardone, R.A., Marzulli, D., Reshkin, S.J., Casavola, V., and Zaccolo, M. (2012). CFTR regulation in human airway epithelial cells requires integrity of the actin cytoskeleton and compartmentalized cAMP and PKA activity. J. Cell Sci.","DOI":"10.1242\/jcs.089086"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Sheng, R., Chen, Y., Yung Gee, H., Stec, E., Melowic, H.R., Blatner, N.R., Tun, M.P., Kim, Y., K\u00e4llberg, M., and Fujiwara, T.K. (2012). Cholesterol modulates cell signaling and protein networking by specifically interacting with PDZ domain-containing scaffold proteins. Nat. Commun.","DOI":"10.1038\/ncomms2221"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Baroni, D., Zegarra-Moran, O., Svensson, A., and Moran, O. (2014). Direct interaction of a cftr potentiator and a cftr corrector with phospholipid bilayers. Eur. Biophys. J.","DOI":"10.1007\/s00249-014-0956-y"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Chin, S., Hung, M., Won, A., Wu, Y.S., Ahmadi, S., Yang, D., Elmallah, S., Toutah, K., Hamilton, C.M., and Young, R.N. (2018). Lipophilicity of the cystic fibrosis drug, ivacaftor (VX-770), and its destabilizing effect on the major CF-causing mutation: F508del s. Mol. Pharmacol.","DOI":"10.1124\/mol.118.112177"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Liu, F., Zhang, Z., Levit, A., Levring, J., Touhara, K.K., Shoichet, B.K., and Chen, J. (2019). Structural identification of a hotspot on CFTR for potentiation. Science.","DOI":"10.1126\/science.aaw7611"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Chiricozzi, E., Lunghi, G., Di Biase, E., Fazzari, M., Sonnino, S., and Mauri, L. (2020). GM1 ganglioside is a key factor in maintaining the mammalian neuronal functions avoiding neurodegeneration. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030868"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Itokazu, Y., Pagano, R.E., Schroeder, A.S., O\u2019Grady, S.M., Limper, A.H., and Marks, D.L. (2014). Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased \u03b21-integrin signaling and delayed wound repair. Am. J. Physiol. Cell Physiol.","DOI":"10.1152\/ajpcell.00168.2013"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.chemphyslip.2016.08.002","article-title":"Unravelling the role of sphingolipids in cystic fibrosis lung disease","volume":"200","author":"Aureli","year":"2016","journal-title":"Chem. Phys. Lipids"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Abu-Arish, A., Pandzic, E., Goepp, J., Matthes, E., Hanrahan, J.W., and Wiseman, P.W. (2015). Cholesterol Modulates CFTR Confinement in the Plasma Membrane of Primary Epithelial Cells. Biophys. J.","DOI":"10.1016\/j.bpj.2015.04.042"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sondo, E., Tomati, V., Caci, E., Esposito, A.I., Pfeffer, U., Pedemonte, N., and Galietta, L.J.V. (2011). Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am. J. Physiol. Cell Physiol.","DOI":"10.1152\/ajpcell.00507.2010"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Scudieri, P., Caci, E., Bruno, S., Ferrera, L., Schiavon, M., Sondo, E., Tomati, V., Gianotti, A., Zegarra-Moran, O., and Pedemonte, N. (2012). Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. J. Physiol.","DOI":"10.1113\/jphysiol.2012.240838"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Chiricozzi, E., Biase, E., Di Maggioni, M., Lunghi, G., Fazzari, M., Pom\u00e8, D.Y., Casellato, R., Loberto, N., Mauri, L., and Sonnino, S. (2019). GM1 promotes TrkA-mediated neuroblastoma cell differentiation by occupying a plasma membrane domain different from TrkA. J. Neurochem.","DOI":"10.1111\/jnc.14685"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chiricozzi, E., Pom\u00e8, D.Y., Maggioni, M., Di Biase, E., Parravicini, C., Palazzolo, L., Loberto, N., Eberini, I., and Sonnino, S. (2017). Role of the GM1 ganglioside oligosaccharide portion in the TrkA-dependent neurite sprouting in neuroblastoma cells. J. Neurochem.","DOI":"10.1111\/jnc.14146"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sondo, E., Falchi, F., Caci, E., Ferrera, L., Giacomini, E., Pesce, E., Tomati, V., Mandrup Bertozzi, S., Goldoni, L., and Armirotti, A. (2018). Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. Cell Chem. Biol.","DOI":"10.1016\/j.chembiol.2018.04.010"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Wu, G., and Ledeen, R. (1988). Quantification of gangliotetraose gangliosides with cholera toxin. Anal. Biochem.","DOI":"10.1016\/0003-2697(88)90201-1"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Chiricozzi, E., Mauri, L., Lunghi, G., Di Biase, E., Fazzari, M., Maggioni, M., Valsecchi, M., Prioni, S., Loberto, N., and Pom\u00e8, D.Y. (2019). Parkinson\u2019s disease recovery by GM1 oligosaccharide treatment in the B4galnt1 +\/\u2212 mouse model. Sci. Rep.","DOI":"10.1038\/s41598-019-55885-2"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4486\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:42:12Z","timestamp":1760175732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/12\/4486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":49,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21124486"],"URL":"https:\/\/doi.org\/10.3390\/ijms21124486","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}